FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte spheroids to treat degenerative joints.

Degenerative joint disease affects millions of people worldwide and is one of the leading causes of chronic pain and disability. Cartilage has a limited natural capacity to heal, and once it is damaged, patients often progress toward invasive surgical interventions, including total joint replacement. There remains a significant unmet need for less invasive, lower cost treatment options that repair damaged cartilage rather than replace the joint itself.